The Birth of the Psychedelic Industry: Capitalizing on the Psychedelic Renaissance
Summary
Psychedelics like psilocybin, LSD, and MDMA are being reevaluated as potential mental health treatments, amidst concerns over commercialization. The study explores the emerging pharmaco-psychotherapy industry through interviews with stakeholders, revealing the complex relationships between researchers and venture capitalists. It highlights ethical dilemmas faced by scientists regarding their ties to private investors and the influence of economic conditions on scientific practices, suggesting a need for a reassessment of these dynamics.
Study at a glance
| Design | qualitative study |
|---|---|
| Population | stakeholders in the pharmaco-psychotherapy industry |
| Key finding | The study uncovers ethical dilemmas faced by scientists in psychedelic medicine due to their mixed interests with private investors. |
Abstract
Recent scientific findings spanning the past two decades have prompted a reevaluation of psychedelics, including psilocybin, LSD, and MDMA, as potent tools for mental health treatment. While these substances were historically associated with countercultural movements, concerns and excitement arise as they become commercialized. Based on in-depth interviews of relevant stakeholders of the scene, this study investigates the emergence of the pharmaco-psychotherapy industry and explores the ambiguity between a supposedly ‘impartial scientific community’ and ‘profit-driven pharmaceutical companies’ in the context of Western psychedelia. The paper unveils the intricate network of relationships between researchers, academics, and venture capitalists (VCs), emphasizing the dual role of VCs as financial backers and conduits for regulatory insights and industry knowledge. The study also uncovers the ethical dilemmas faced by scientists in psychedelic medicine, including their mixed interests with private investors, where transformative qualities of psychedelic experience perturb the clear-cut line between objectivity and subjectivity. In particular, researchers’ hesitancy to disclose personal experiences with these substances throughout the interviewing process reflects a shift from the ’illegality’ paradigm to ’intellectual property’ in pharmaceutical innovation. Based on the findings, we suggest a need to reconsider the ethical dynamics in scientific practices, by taking into account the economic preconditions of infrastructural designs, particularly the impact of public/private fundraisers, to whom scientists are likely to make efforts to align with their expectations.